Alnylam announced top-line results from a Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus infection in lung transplant patients. The primary endpoint of the study was the incidence of new or progressive bronchiolitis obliterans syndrome at 180 days after RSV infection. The study missed the primary endpoint of reduced BOS in an "intent-to-treat" analysis of confirmed RSV infected patients, but achieved statistically significant reductions in prospectively defined analyses of ITTc patients with their "last observation carried forward" with a p-value of 0.028, and of ITTc patients treated "per protocol" with a p-value of 0.025. In all analyses, ALN-RSV01 treatment was associated with a clinically meaningful treatment effect, with a reduction of over 50% in the incidence of day 180 BOS as compared with placebo.
There’s just about no tolerance left in America for wealthy people griping about their financial woes. But is it …